down arrow

China Regenerative Medicine International Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG2129W1380
  • HKG: 8158
HKD
0.23
-0.18 (-44.2%)

Sep 23

HKG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Consun Pharmaceutical Group Ltd.
Tong Ren Tang Technologies Co., Ltd.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
CStone Pharmaceuticals Co. Ltd.
3D Medicines, Inc.
Shanghai Junshi Biosciences Co., Ltd.
CARsgen Therapeutics Holdings Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
China Regenerative Medicine International Ltd.

Why is China Regenerative Medicine International Ltd. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is China Regenerative Medicine International Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
China Regenerative Medicine International Ltd.
-100.0%
0.28
86.24%
Hang Seng Hong Kong
-5.07%
-0.26
18.70%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
235.57%
EBIT Growth (5y)
-201.79%
EBIT to Interest (avg)
-30.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.09
Sales to Capital Employed (avg)
4.65
Tax Ratio
6.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.76
EV to EBIT
-0.57
EV to EBITDA
-0.76
EV to Capital Employed
1.49
EV to Sales
0.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-262.74%
ROE (Latest)
-409.54%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
NET SALES(Q)

At HKD 41.73 MM has Grown at 52.36%

-2What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 11.98% (YoY

INTEREST(Q)

Highest at HKD 1.06 MM

Here's what is working for China Regenerative Medicine International Ltd.

Net Sales
At HKD 41.73 MM has Grown at 52.36%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (HKD MM)

Here's what is not working for China Regenerative Medicine International Ltd.

Interest
Highest at HKD 1.06 MM
in the last five periods and Increased by 94.69% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Raw Material Cost
Grown by 11.98% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading